What smart money is saying about Iovance
IOVA
No fund has written a full thesis on Iovance in our archive, but 2 fund letters report a position in it — most recently Rhenman Healthcare Equity L/S in October 2026.
Get an email when a fund buys, sells or pitches it
2
Reported positions
0
Bought
0
Sold
2
Letters
Position history
Between Q3 2026 and Q4 2026, 2 fund letters reported a position in Iovance, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2026 | 1 | 0 | 0 | 0 |
| Q3 2026 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions
- HoldsRhenman Healthcare Equity L/SOctober 2026
“The largest negative contributions came from Iovance and Axsome.”
Iovance - HoldsRhenman Healthcare Equity L/SAugust 2026
“The best contributors for the month were all biopharma names, including Iovance, Insmed and Merck.”
Iovance
Read the letters behind these Iovance positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger